British Journal of Dermatology最新文献

筛选
英文 中文
Beneath the surface: a case of subcutaneous human dirofilariasis. 表面之下:一例皮下人类丝虫病。
IF 3.5 1区 医学
British Journal of Dermatology Pub Date : 2024-11-18 DOI: 10.1093/bjd/ljae299
Bhukampa Acharya, Anubha Dev, Anindita Sinha, Parmod Kumar, Dipankar De, Rahul Mahajan
{"title":"Beneath the surface: a case of subcutaneous human dirofilariasis.","authors":"Bhukampa Acharya, Anubha Dev, Anindita Sinha, Parmod Kumar, Dipankar De, Rahul Mahajan","doi":"10.1093/bjd/ljae299","DOIUrl":"10.1093/bjd/ljae299","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"1030"},"PeriodicalIF":3.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bridging the gap: validating the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure. 缩小差距:验证 "患者报告的皮肤病影响"(PRIDD)指标。
IF 3.5 1区 医学
British Journal of Dermatology Pub Date : 2024-11-18 DOI: 10.1093/bjd/ljae315
Junfen Zhang, Bin Yang
{"title":"Bridging the gap: validating the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure.","authors":"Junfen Zhang, Bin Yang","doi":"10.1093/bjd/ljae315","DOIUrl":"10.1093/bjd/ljae315","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"861"},"PeriodicalIF":3.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure. 患者报告的皮肤病影响(PRIDD)测量方法的测量特性和可解释性。
IF 3.5 1区 医学
British Journal of Dermatology Pub Date : 2024-11-18 DOI: 10.1093/bjd/ljae267
Rachael Pattinson, Nirohshah Trialonis-Suthakharan, Tim Pickles, Jennifer Austin, Allison FitzGerald, Matthias Augustin, Christine Bundy
{"title":"Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure.","authors":"Rachael Pattinson, Nirohshah Trialonis-Suthakharan, Tim Pickles, Jennifer Austin, Allison FitzGerald, Matthias Augustin, Christine Bundy","doi":"10.1093/bjd/ljae267","DOIUrl":"10.1093/bjd/ljae267","url":null,"abstract":"<p><strong>Background: </strong>Patient-reported outcome measures (PROMs) are crucial in assessing the impact of dermatological conditions on people's lives, but the existing dermatology-specific PROMs are not recommended for use, according to COSMIN. We developed the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure in partnership with patients. It has strong evidence of content validity, structural validity, internal consistency, acceptability and feasibility.</p><p><strong>Objectives: </strong>To test the remaining measurement properties of the PRIDD and establish the interpretability of scores against the COSMIN criteria, using classic and modern psychometric methods.</p><p><strong>Methods: </strong>A global longitudinal study consisting of two online surveys administered 2-4 weeks apart was carried out. Adults (≥ 18 years of age) living with a dermatological condition were recruited via the International Alliance of Dermatology Patient Organizations' (GlobalSkin) membership network. Participants completed PRIDD, a demographics questionnaire and other related measures, including the Dermatology Life Quality Index. We tested the criterion validity, construct validity and responsiveness (Spearman's ρ, independent-samples t-tests and Anova); test-retest reliability [interclass correlation coefficient (ICC)]; measurement error [smallest detectable change or limits of agreement (LoA), distribution-based minimally important change (MIC)]; floor and ceiling effects (number of minimum and maximum scores and person-item location distribution maps), score bandings (κ coefficient of agreement) and the anchor-based MIC of the PRIDD.</p><p><strong>Results: </strong>In total, 504 people with 35 dermatological conditions from 38 countries participated. Criterion validity (ρ = 0.79), construct validity (76% hypotheses met), test-retest validity (ICC = 0.93) and measurement error (LoA = 1.3 < MIC = 4.14) were sufficient. Floor and ceiling effects were in the acceptable range (< 15%). Score bandings were determined (κ = 0.47); however, the anchor-based MIC could not be calculated owing to an insufficient anchor.</p><p><strong>Conclusions: </strong>PRIDD is a valid and reliable tool to evaluate the impact of dermatological disease on people's lives in research and clinical practice. It is the first dermatology-specific PROM to meet the COSMIN criteria. These results support the value of developing and validating PROMs with a patient-centred approach and using classic and modern psychometric methods. Further testing of responsiveness and MIC, cross-cultural translation, linguistic validation and global data collection are planned.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"936-948"},"PeriodicalIF":3.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141455438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The emerging burden of melanoma overdiagnosis in Australia. Who bears the cost: patients or the healthcare system? 澳大利亚新出现的黑色素瘤过度诊断负担:谁来承担成本--患者还是医疗系统?
IF 3.5 1区 医学
British Journal of Dermatology Pub Date : 2024-11-18 DOI: 10.1093/bjd/ljae339
Rashidul Alam Mahumud
{"title":"The emerging burden of melanoma overdiagnosis in Australia. Who bears the cost: patients or the healthcare system?","authors":"Rashidul Alam Mahumud","doi":"10.1093/bjd/ljae339","DOIUrl":"10.1093/bjd/ljae339","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"859-860"},"PeriodicalIF":3.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Life's Essential 8, genetic susceptibility and the risk of psoriatic disease: a prospective cohort study. 人生必修 8》、遗传易感性和银屑病患病风险:一项前瞻性队列研究。
IF 3.5 1区 医学
British Journal of Dermatology Pub Date : 2024-11-18 DOI: 10.1093/bjd/ljae268
Fujun Ouyang, Honghao Yang, Zhenghong Di, Jiahao Hu, Yuan Ding, Chao Ji, Yashu Liu, Liangkai Chen, Yang Xia
{"title":"Life's Essential 8, genetic susceptibility and the risk of psoriatic disease: a prospective cohort study.","authors":"Fujun Ouyang, Honghao Yang, Zhenghong Di, Jiahao Hu, Yuan Ding, Chao Ji, Yashu Liu, Liangkai Chen, Yang Xia","doi":"10.1093/bjd/ljae268","DOIUrl":"10.1093/bjd/ljae268","url":null,"abstract":"<p><strong>Background: </strong>Psoriatic disease (PsD) is closely associated with cardiovascular (CV) disease. The Life's Essential 8 (LE8) score is a new metric to assess CV health (CVH), where a higher score indicates better CVH. However, the longitudinal association between LE8 score and the risk of PsD remains uncertain.</p><p><strong>Objectives: </strong>To investigate, in a cohort study, the association between LE8 score, genetic susceptibility and the risk of PsD.</p><p><strong>Methods: </strong>This cohort study included 261 642 participants in the UK Biobank without PsD at baseline. LE8 comprises eight indicators: diet, physical activity, nicotine exposure, sleep health, body mass index, blood lipids, blood glucose and blood pressure. Cox proportional hazard models were used to examine the association between participants' LE8 scores, genetic risk of PsD and the risk of PsD. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated.</p><p><strong>Results: </strong>During an average follow-up of 12.3 years, 1501 participants developed PsD. Compared with participants with low LE8 scores, the HRs of developing PsD for those with moderate and high LE8 scores were 0.51 (95% CI 0.43-0.59) and 0.34 (95% CI 0.27-0.42) after adjustments, respectively. Dose-response analysis revealed a linear negative association between continuous LE8 score and the risk of developing PsD (P < 0.001), with no evidence of nonlinear association detected. Genetic susceptibility to PsD did not modify this association (P-interaction = 0.63). Subgroup analyses revealed that women had a more pronounced beneficial association between LE8 scores and PsD risk (P-interaction = 0.02).</p><p><strong>Conclusions: </strong>Our study suggests that a higher LE8 score, regardless of genetic risk, is associated with a lower risk of PsD, particularly in women. Consequently, maintaining good CVH status is recommended to prevent PsD and assess associated risks.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"897-905"},"PeriodicalIF":3.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind placebo-controlled study (ViDMe trial). 大剂量维生素 D 补充剂不会改善皮肤黑色素瘤患者的预后:一项随机双盲安慰剂对照研究(ViDMe 试验)的结果。
IF 11 1区 医学
British Journal of Dermatology Pub Date : 2024-11-18 DOI: 10.1093/bjd/ljae257
Julie De Smedt, Sofie Van Kelst, Laudine Janssen, Vivien Marasigan, Veerle Boecxstaens, Kris Bogaerts, Ann Belmans, Dirk Vanderschueren, Katleen Vandenberghe, Oliver Bechter, Claudia Aura, Diether Lambrechts, Tinne Strobbe, Gabriella Emri, Arjen Nikkels, Marjan Garmyn
{"title":"High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind placebo-controlled study (ViDMe trial).","authors":"Julie De Smedt, Sofie Van Kelst, Laudine Janssen, Vivien Marasigan, Veerle Boecxstaens, Kris Bogaerts, Ann Belmans, Dirk Vanderschueren, Katleen Vandenberghe, Oliver Bechter, Claudia Aura, Diether Lambrechts, Tinne Strobbe, Gabriella Emri, Arjen Nikkels, Marjan Garmyn","doi":"10.1093/bjd/ljae257","DOIUrl":"10.1093/bjd/ljae257","url":null,"abstract":"<p><strong>Background: </strong>Observational studies in cutaneous melanoma (CM) have indicated an inverse relationship between levels of 25-hydroxyvitamin D and Breslow thickness, in addition to a protective effect of high 25-hydroxyvitamin D levels on clinical outcome.</p><p><strong>Objectives: </strong>To evaluate whether high-dose vitamin D supplementation in curatively resected CM reduces melanoma relapse.</p><p><strong>Methods: </strong>In a prospective randomized double-blind placebo-controlled trial, 436 patients with resected CM stage IA to III (8th American Joint Committee on Cancer staging) were randomized. Among them, 218 received a placebo while 218 received monthly 100 000 IU cholecalciferol for a minimum of 6 months and a maximum of 42 months (treatment arm). Following randomization, patients were followed for a median of 52 months, with a maximum follow-up of 116 months. The primary endpoint was relapse-free survival. Secondary endpoints were melanoma-related mortality, overall survival, and the evolution of 25-hydroxyvitamin D serum levels over time.</p><p><strong>Results: </strong>In our population (mean age 55 years, 54% female sex) vitamin D supplementation increased 25-hydroxyvitamin D serum levels after 6 months of supplementation in the treatment arm by a median 17 ng mL-1 [95% confidence interval (CI) 9-26] compared with 0 ng mL-1 (95% CI 6-8) in the placebo arm (P < 0.001, Wilcoxon test) and remained at a steady state during the whole treatment period. The estimated event rate for relapse-free survival at 72 months after inclusion was 26.51% in the vitamin D supplemented arm (95% CI 19.37-35.64) vs. 20.70% (95% CI 14.26-29.52) in the placebo arm (hazard ratio 1.27, 95% CI 0.79-2.03; P = 0.32). After adjusting for confounding factors (including baseline stage, body mass index, age, sex and baseline season), the hazard ratio was 1.20 (95% CI 0.74-1.94, P = 0.46). The number of deaths from progression of CM and nonmelanoma-related deaths was similar in both the vitamin D supplemented and placebo groups (deaths from progression of CM, n = 10 and n = 11, respectively; nonmelanoma-related deaths, n = 3 and n = 2, respectively). No major adverse events were observed during the study.</p><p><strong>Conclusions: </strong>In patients with CM, monthly high-dose vitamin D supplementation was safe, resulted in a sustained increase in 25-hydroxyvitamin D levels during the treatment period, but did not improve relapse-free survival, melanoma-related death or overall survival.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"886-896"},"PeriodicalIF":11.0,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overlapping itch assessments in the Harmonizing Outcome Measures for Eczema core outcome set for eczema clinical trials: is redundancy necessary? 湿疹临床试验 "HOME "核心结果集中重叠的瘙痒评估:冗余是否必要?
IF 3.5 1区 医学
British Journal of Dermatology Pub Date : 2024-11-18 DOI: 10.1093/bjd/ljae304
Arabella Baker, Riya Patel, Beth Stuart, Kim S Thomas
{"title":"Overlapping itch assessments in the Harmonizing Outcome Measures for Eczema core outcome set for eczema clinical trials: is redundancy necessary?","authors":"Arabella Baker, Riya Patel, Beth Stuart, Kim S Thomas","doi":"10.1093/bjd/ljae304","DOIUrl":"10.1093/bjd/ljae304","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"1020-1021"},"PeriodicalIF":3.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141854852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinically mild hidradenitis suppurativa: mild for whom? 临床轻度化脓性扁桃体炎:对谁来说是轻度?
IF 3.5 1区 医学
British Journal of Dermatology Pub Date : 2024-11-18 DOI: 10.1093/bjd/ljae310
Tonia Samela, Giulia Raimondi, Giusi Pintori, Maria Beatrice Pupa, Giorgia Cordella, Valeria Antinone, Nidia Melo Salcedo, Roberta Fusari, Sabatino Pallotta, Francesca Sampogna, Luca Fania, Davide Ciccone, Giovanni Pellacani, Damiano Abeni
{"title":"Clinically mild hidradenitis suppurativa: mild for whom?","authors":"Tonia Samela, Giulia Raimondi, Giusi Pintori, Maria Beatrice Pupa, Giorgia Cordella, Valeria Antinone, Nidia Melo Salcedo, Roberta Fusari, Sabatino Pallotta, Francesca Sampogna, Luca Fania, Davide Ciccone, Giovanni Pellacani, Damiano Abeni","doi":"10.1093/bjd/ljae310","DOIUrl":"10.1093/bjd/ljae310","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"1026-1027"},"PeriodicalIF":3.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142054961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-centre cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. 特应性皮炎患者的杜匹单抗相关(高)嗜酸性粒细胞增多症:TREAT NL(荷兰特应性湿疹治疗)登记处的单中心队列研究。
IF 3.5 1区 医学
British Journal of Dermatology Pub Date : 2024-11-18 DOI: 10.1093/bjd/ljae289
Angelo Li, Annelie H Musters, Ariënna Hyseni, Louise A A Gerbens, Phyllis I Spuls
{"title":"Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-centre cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.","authors":"Angelo Li, Annelie H Musters, Ariënna Hyseni, Louise A A Gerbens, Phyllis I Spuls","doi":"10.1093/bjd/ljae289","DOIUrl":"10.1093/bjd/ljae289","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"1012-1013"},"PeriodicalIF":3.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sensitization against medical hyaluronidase in patients with confirmed hypersensitivity against hymenoptera species and its clinical implications. 已确认对膜翅目物种过敏的患者对医用透明质酸酶的过敏反应及其临床意义。
IF 3.5 1区 医学
British Journal of Dermatology Pub Date : 2024-11-18 DOI: 10.1093/bjd/ljae290
Mattis Bertlich, Daniela Hartmann, Saskia Freytag, Lars E French, Eva Oppel
{"title":"Sensitization against medical hyaluronidase in patients with confirmed hypersensitivity against hymenoptera species and its clinical implications.","authors":"Mattis Bertlich, Daniela Hartmann, Saskia Freytag, Lars E French, Eva Oppel","doi":"10.1093/bjd/ljae290","DOIUrl":"10.1093/bjd/ljae290","url":null,"abstract":"<p><strong>Background: </strong>Hyaluronidase is an ubiquitous enzyme, present, among others, in hymenoptera venom and in medical formulations. The latter include use as an emergency treatment or to correct undesired outcomes of medical and aesthetic procedures using hyaluronic acid fillers.</p><p><strong>Objectives: </strong>By performing detailed allergy work-ups including skin-prick tests (SPTs) we investigated whether patients with a history of allergic reaction to hymenoptera venom are also sensitized to medical grade hyaluronidase.</p><p><strong>Methods: </strong>Ninety patients with a history of type-1 reaction to hymenoptera venom with and without a history of previous specific venom immunotherapy were included in the study. All underwent SPTs for medical hyaluronidase. All patients also underwent serological analysis for Api m2, the only commercially available IgE test for a hymenoptera hyaluronidase.</p><p><strong>Results: </strong>Of the 90 patients with previous type-1 reactions to hymenoptera venom hyaluronidase included in the study, 60 had undergone previous venom immunotherapy; 30 did not. The majority (73 of 90) were allergic to wasps, followed by honeybees (14 of 90) and three were allergic to both. Neither patients having undergone previous immunotherapy nor those allergic to bees showed positive SPTs to medical hyaluronidase. Of those with a wasp allergy and naïve to immunotherapy, over 20% (5 of 23) showed positive SPTs to medical hyaluronidase. Healthy controls (0 of 30) without previous allergic reactions to hymenoptera did not show positive SPTs to medical hyaluronidase.</p><p><strong>Conclusions: </strong>Sensitization to hyaluronidase is most common in wasp-allergic patients who have not had previous specific immunotherapy. As allergic reactions to medical hyaluronidase are reported to be scarce, this group is probably at the highest risk to develop anaphylaxis to medical hyaluronidase. While all patients with untreated anaphylaxis to hymenoptera venom should consult an allergy specialist, it is particularly important that those with untreated wasp allergies seek specialist advice before treatment with medical hyaluronidase is initiated.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"1000-1007"},"PeriodicalIF":3.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信